Literature DB >> 20585280

Murine cytomegalovirus infection leads to increased levels of transplant arteriosclerosis in a murine aortic allograft model.

Christian Heim1, Silke Abele-Ohl, Sebastian Eckl, Martina Ramsperger-Gleixner, Shohreh Mahmoudian, Michael Weyand, Thomas Stamminger, Stephan M Ensminger.   

Abstract

INTRODUCTION: Cytomegalovirus infection after heart transplantation is considered as risk factor for the development of transplant arteriosclerosis. Therefore, the aim of this study was to investigate the effect of murine cytomegalovirus (MCMV) as a single risk factor on transplant arteriosclerosis in an experimental aortic allograft model.
METHODS: Major histocompatibility complex class I-mismatched aortas of C.B10-H2(b)/LilMcdJ donor were transplanted into BALB/c recipients, which were either mock-infected or infected with MCMV (strain Smith) on day 7 and harvested 37 days after transplantation. In one experimental group animals received a daily dose of everolimus to increase the viral load of recipients. Grafts were analyzed by histology, morphometry, and immunofluorescence. Intragraft cytokine mRNA production was analyzed by real-time polymerase chain reaction (PCR), and persistence of cytomegalovirus infection was confirmed by TaqMan PCR.
RESULTS: After infection with MCMV, there was significantly more intimal proliferation when compared with uninfected controls (intimal proliferation 83.5%+/-9.6% [MCMV] vs. 43.9%+/-5.1% [MCMV]), indicating that MCMV plays a role in the development of transplant arteriosclerosis. Even after treatment with everolimus, MCMV infection pronounced significantly more intimal proliferation (intimal proliferation 52.5%+/-7.3% [MCMV] vs. 20.2%+/-1.7% [MCMV]). Intragraft mRNA expression showed significantly higher production of CD62E, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 after infection with MCMV. Cellular infiltration revealed significantly more CD4, CD8, and dendritic cells. We could also confirm the presence of MCMV for the duration of the experimental protocol by PCR within the spleen, liver, salivary glands, lung, and the aortic transplant.
CONCLUSION: These data suggest that MCMV infection plays an important role in the development of transplant arteriosclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585280     DOI: 10.1097/TP.0b013e3181e8a699

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  [Heart and combined heart-lung transplantation. Indications, chances and risks].

Authors:  T Puehler; S Ensminger; U Schulz; U Fuchs; K Tigges-Limmer; J Börgermann; M Morshuis; K Hakim; O Oldenburg; J Niedermeyer; A Renner; J Gummert
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

2.  Prolyl-hydroxylase inhibitor activating hypoxia-inducible transcription factors reduce levels of transplant arteriosclerosis in a murine aortic allograft model.

Authors:  Christian Heim; Wanja Bernhardt; Sabina Jalilova; Zhendi Wang; Benjamin Motsch; Martina Ramsperger-Gleixner; Nicolai Burzlaff; Michael Weyand; Kai-Uwe Eckardt; Stephan M Ensminger
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-01-27

3.  RCMV increases intimal hyperplasia by inducing inflammation, MCP-1 expression and recruitment of adventitial cells to intima.

Authors:  Cecilia Söderberg-Nauclér; Piotr Religa; Monika K Grudzinska; Krzysztof Bojakowski; Joanna Soin; Frank Stassen
Journal:  Herpesviridae       Date:  2010-12-23

4.  AP-1 Oligodeoxynucleotides Reduce Aortic Elastolysis in a Murine Model of Marfan Syndrome.

Authors:  Rawa Arif; Marcin Zaradzki; Anca Remes; Philipp Seppelt; Reiner Kunze; Hannes Schröder; Simon Schwill; Stephan M Ensminger; Peter N Robinson; Matthias Karck; Oliver J Müller; Markus Hecker; Andreas H Wagner; Klaus Kallenbach
Journal:  Mol Ther Nucleic Acids       Date:  2017-09-20

Review 5.  Don't Go Breaking My Heart: MCMV as a Model for HCMV-Associated Cardiovascular Diseases.

Authors:  Cassandra M Bonavita; Rhonda D Cardin
Journal:  Pathogens       Date:  2021-05-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.